anti-ROBO1 single-domain antibody

The anti-ROBO1 single-domain antibody is an engineered therapeutic agent designed to target the Roundabout guidance receptor 1 (ROBO1), a protein involved in axon guidance pathways that are exploited by highly invasive brain cancers. Developed by a collaborative group including McMaster University and the National Research Council Canada, this antibody was identified as a means to disrupt the PTP4A2-ROBO1 signaling axis, which drives self-renewal, proliferation, and tumorigenicity in recurrent glioblastoma (GBM). By binding to ROBO1, the single-domain antibody mimics the effects of PTP4A2 inhibition, repressing the invasive activity of tumor cells. Beyond its use as a standalone agent, this antibody has been utilized as the targeting domain for second-generation chimeric antigen receptor (CAR)-T cell therapies, which have demonstrated potent anti-tumor responses in preclinical models of recurrent glioblastoma, medulloblastoma, and lung-to-brain metastases.

Other names

anti-ROBO1 sdAbanti-ROBO-1 sdAbanti-ROBO 1 sdAbanti-ROBO1 nanobodyanti-ROBO-1 nanobodyanti-ROBO 1 nanobody